guest ::
| Home > Publications database > Activating Natural Killer Cell Receptors, Selectins, and Inhibitory Siglecs Recognize Ebolavirus Glycoprotein. > print |
| Home > Publications database > Activating Natural Killer Cell Receptors, Selectins, and Inhibitory Siglecs Recognize Ebolavirus Glycoprotein. > print |
| 001 | 170400 | ||
| 005 | 20240229133712.0 | ||
| 024 | 7 | _ | |a 10.1159/000517628 |2 doi |
| 024 | 7 | _ | |a pmid:34425576 |2 pmid |
| 024 | 7 | _ | |a 1662-811X |2 ISSN |
| 024 | 7 | _ | |a 1662-8128 |2 ISSN |
| 024 | 7 | _ | |a altmetric:112257191 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2021-01907 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Jarahian, Mostafa |0 P:(DE-He78)3ac0bc7cf0e8ab1e1bc05c7889bfa3df |b 0 |e First author |
| 245 | _ | _ | |a Activating Natural Killer Cell Receptors, Selectins, and Inhibitory Siglecs Recognize Ebolavirus Glycoprotein. |
| 260 | _ | _ | |a Sydney |c 2022 |b Karger |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1649167699_16165 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:G401# / 2022;14(2):135-147 |
| 520 | _ | _ | |a Expression of the extensively glycosylated Ebolavirus glycoprotein (EBOV-GP) induces physical alterations of surface molecules and plays a crucial role in viral pathogenicity. Here we investigate the interactions of EBOV-GP with host surface molecules using purified EBOV-GP, EBOV-GP-transfected cell lines, and EBOV-GP-pseudotyped lentiviral particles. Subsequently, we wanted to examine which receptors are involved in this recognition by binding studies to cells transfected with the EBOV-GP as well as to recombinant soluble EBOV-GP. As the viral components can also bind to inhibitory receptors of immune cells (e.g., Siglecs, TIM-1), they can even suppress the activity of immune effector cells. Our data show that natural killer (NK) cell receptors NKp44 and NKp46, selectins (CD62E/P/L), the host factors DC-SIGNR/DC-SIGN, and inhibitory Siglecs function as receptors for EBOV-GP. Our results show also moderate to strong avidity of homing receptors (P-, L-, and E-selectin) and DC-SIGNR/DC-SIGN to purified EBOV-GP, to cells transfected with EBOV-GP, as well as to the envelope of a pseudotyped lentiviral vector carrying the EBOV-GP. The concomitant activation and inhibition of the immune system exemplifies the evolutionary antagonism between the immune system and pathogens. Altogether these interactions with activating and inhibitory receptors result in a reduced NK cell-mediated lysis of EBOV-GP-expressing cells. Modulation of these interactions may provide new strategies for treating infections caused by this virus. |
| 536 | _ | _ | |a 314 - Immunologie und Krebs (POF4-314) |0 G:(DE-HGF)POF4-314 |c POF4-314 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de |
| 650 | _ | 7 | |a Ebolavirus glycoprotein |2 Other |
| 650 | _ | 7 | |a HPV |2 Other |
| 650 | _ | 7 | |a Natural cytotoxicity receptors |2 Other |
| 650 | _ | 7 | |a Selectins |2 Other |
| 650 | _ | 7 | |a Siglecs |2 Other |
| 700 | 1 | _ | |a Marstaller, Katharina |0 P:(DE-He78)ca88d821f0916f86f2e3b130f9cbe1eb |b 1 |
| 700 | 1 | _ | |a Banna, Nadine |0 P:(DE-He78)e33dd4f0f85f24d38c389c3e9fa46854 |b 2 |u dkfz |
| 700 | 1 | _ | |a Ahani, Roshanak |b 3 |
| 700 | 1 | _ | |a Etemadzadeh, Mohammad Hossein |b 4 |
| 700 | 1 | _ | |a Boller, Lea K |b 5 |
| 700 | 1 | _ | |a Azadmanesh, Kayhan |b 6 |
| 700 | 1 | _ | |a Cid-Arregui, Angel |0 P:(DE-He78)a30064f6b2d9ab959d35315d7668c091 |b 7 |u dkfz |
| 700 | 1 | _ | |a Khezri, Abdolrahman |b 8 |
| 700 | 1 | _ | |a Berger, Martin R |0 P:(DE-He78)7e60033e3eaaebb9ba30c905ade4a676 |b 9 |u dkfz |
| 700 | 1 | _ | |a Momburg, Frank |0 P:(DE-He78)b2290261145f21c46f2d42783c69d104 |b 10 |u dkfz |
| 700 | 1 | _ | |a Watzl, Carsten |b 11 |
| 773 | _ | _ | |a 10.1159/000517628 |g p. 1 - 13 |0 PERI:(DE-600)2455818-7 |n 2 |p 135-147 |t Journal of innate immunity |v 14 |y 2022 |x 1662-8128 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:170400 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)ca88d821f0916f86f2e3b130f9cbe1eb |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)e33dd4f0f85f24d38c389c3e9fa46854 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-He78)a30064f6b2d9ab959d35315d7668c091 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-He78)7e60033e3eaaebb9ba30c905ade4a676 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-He78)b2290261145f21c46f2d42783c69d104 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-314 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Immunologie und Krebs |x 0 |
| 914 | 1 | _ | |y 2021 |
| 915 | _ | _ | |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND (No Version) |0 LIC:(DE-HGF)CCBYNCNDNV |2 V:(DE-HGF) |b DOAJ |d 2021-01-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-01-27 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-27 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2021-01-27 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2021-01-27 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2021-01-27 |
| 915 | _ | _ | |a National-Konsortium |0 StatID:(DE-HGF)0430 |2 StatID |d 2022-11-12 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2022-01-20T09:11:45Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2022-01-20T09:11:45Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Blind peer review |d 2022-01-20T09:11:45Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2022-11-12 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J INNATE IMMUN : 2021 |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-12 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-12 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b J INNATE IMMUN : 2021 |d 2022-11-12 |
| 920 | 1 | _ | |0 I:(DE-He78)G401-20160331 |k G401 |l Molekulare Toxikologie und Chemotherapie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)D122-20160331 |k D122 |l D122 AG Gezielte Tumorvakzine |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)D121-20160331 |k D121 |l D121 AG Antigenpräsentation und T/NK-Zell-Aktivierung |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)G401-20160331 |
| 980 | _ | _ | |a I:(DE-He78)D122-20160331 |
| 980 | _ | _ | |a I:(DE-He78)D121-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|